|Drugs of the Future|
| || |
|Drugs Fut 2008, 33(6): 473|
Copyright 2008 Clarivate Analytics
Wang, Y., Serradell, N., Rosa, E., Castaner, R.
|BI-1356 is a dipeptidyl-peptidase IV (DPP IV, or CD26) inhibitor developed at Boehringer Ingelheim for the treatment of type 2 diabetes. BI-1356 demonstrated long-lasting DPP IV inhibition both in vitro and in vivo. In vitro, BI-1356 was at least 10,000-fold more selective for DPP IV than for DPP-8 and DPP-9. High potency and long-lasting inhibitory effects were also observed in vivo in mice and rats, the inhibition induced by BI-1356 being longer lasting than that induced by any other DPP IV inhibitor tested. BI-1356 exhibited nonlinear pharmacokinetics in healthy volunteers and patients with type 2 diabetes. Oral BI-1356 administered once daily proved to be well tolerated in healthy volunteers and patients with type 2 diabetes. Treatment with BI-1356 increased concentrations of GLP-1 and reduced concentrations of glucose in patients with type 2 diabetes, and it also significantly reduced Hb1Ac in diabetic patients. Phase III clinical trials are under way.|
Full Text: HTML, PDF
| || |